While initial 2D imaging analysis suggested VBL/MTX delayed the time to tumor progression in pediatric and young adult participants with NF1 and PN, a post hoc 3D analysis determined that VBL/MTX did not result in any PRs, with 47% of those evaluable for volumetric analysis demonstrating PD while on therapy. This evidence concerns the gene NF1 and neoplasm.